- Home
- NBIX vs DAY Comparison
NBIX vs DAY Comparison
Compare NBIX & DAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- DAY
- Stock Information
- Founded
- NBIX 1992
- DAY 1992
- Country
- NBIX United States
- DAY United States
- Employees
- NBIX N/A
- DAY N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- DAY
- Sector
- NBIX Health Care
- DAY
- Exchange
- NBIX Nasdaq
- DAY NYSE
- Market Cap
- NBIX 13.1B
- DAY 12.2B
- IPO Year
- NBIX 1996
- DAY 2018
- Fundamental
- Price
- NBIX $134.99
- DAY $75.57
- Analyst Decision
- NBIX Buy
- DAY Buy
- Analyst Count
- NBIX 23
- DAY 10
- Target Price
- NBIX $165.00
- DAY $81.30
- AVG Volume (30 Days)
- NBIX 884.4K
- DAY 1.5M
- Earning Date
- NBIX 02-05-2025
- DAY 02-07-2025
- Dividend Yield
- NBIX N/A
- DAY N/A
- EPS Growth
- NBIX 97.40
- DAY 1200.52
- EPS
- NBIX 3.73
- DAY 0.34
- Revenue
- NBIX $2,242,800,000.00
- DAY $1,694,500,000.00
- Revenue This Year
- NBIX $27.07
- DAY $16.80
- Revenue Next Year
- NBIX $16.60
- DAY $12.22
- P/E Ratio
- NBIX $36.67
- DAY $230.26
- Revenue Growth
- NBIX 25.72
- DAY 16.85
- 52 Week Low
- NBIX $110.95
- DAY $47.08
- 52 Week High
- NBIX $157.98
- DAY $82.69
- Technical
- Relative Strength Index (RSI)
- NBIX 73.61
- DAY 51.35
- Support Level
- NBIX $125.61
- DAY $76.73
- Resistance Level
- NBIX $130.48
- DAY $78.06
- Average True Range (ATR)
- NBIX 2.67
- DAY 1.56
- MACD
- NBIX 0.90
- DAY -0.67
- Stochastic Oscillator
- NBIX 95.47
- DAY 12.55
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
About DAY DAYFORCE INC
Dayforce provides payroll and human capital management solutions targeting clients with 100-100,000 employees. Following the 2012 acquisition of Dayforce, Dayforce pivoted away from its legacy on-premises Bureau business to become a cloud HCM provider. As of fiscal 2022, about 80% of group revenue was derived from the flagship Dayforce platform geared toward enterprise clients. The remaining revenue is about evenly split between cloud platform Powerpay, targeting small businesses in Canada, and legacy Bureau products.